Trials / Completed
CompletedNCT01919554
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents
Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Stallergenes Greer · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and tolerability of different doses of sublingual tablets of house dust mite (HDM) allergen extracts in adolescents with house dust mite-associated allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 500 IR house dust mites allergen extract tablet | One sublingual tablet daily during 10 days |
| BIOLOGICAL | 1000 IR house dust mites allergen extract tablet | Two sublingual tablets daily during 10 days |
| BIOLOGICAL | 1500 IR house dust mites allergen extract tablet | Three sublingual tablets daily during 10 days |
| BIOLOGICAL | Placebo tablet | One, two or three sublingual placebo tablets daily during 10 days matching with the sublingual immunotherapy tablets |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2013-08-09
- Last updated
- 2025-01-17
- Results posted
- 2025-01-17
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01919554. Inclusion in this directory is not an endorsement.